Fecal microbiota transplantation therapy for Parkinson's disease: A preliminary study
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Imbalances in the gut microbiota mediate the progression of neurodegenerative diseases such as Parkinson's disease (PD). Fecal microbiota transplantation (FMT) is currently being explored as a potential therapy for PD. The objective of this study was to assess the efficacy and safety of FMT on PD. Fifteen PD patients were included, 10 of them received FMT via colonoscopy (colonic FMT group) and 5 received FMT via nasal-jejunal tube (nasointestinal FMT group). The score of PSQI, HAMD, HAMA, PDQ-39, NMSQ and UPDRS-III significantly decreased after FMT treatment (all P < .05). Colonic FMT group showed significant improvement and longer maintenance of efficacy compared with nasointestinal FMT (P = .002). Two patients achieved self-satisfying outcomes that last for more than 24 months. However, nasointestinal FMT group had no significant therapeutic effect, although UPDRS-III score slightly reduced. There were no patients were satisfied with nasointestinal FMT for more than 3 months. Among 15 PD patients, there were 5 cases had adverse events (AEs), including diarrhea (2 cases), abdominal pain (2 cases) and flatulence (1 case). These AEs were mild and self-limiting. We conclude that FMT can relieve the motor and non-motor symptoms with acceptable safety in PD. Compared with nasointestinal FMT, colonic FMT seems better and preferable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three subsequent studies involving 6, 11 and 15 PD patients, respectively, confirmed the reduction in constipation, as well as in motor and non-motor symptoms following FMT, as indicated by the decreased scores registered in various PD assessment tests [475,476,477].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [476]
Experimental — accuracy not yet measuredIn the citing paper
“Concerning PD, consistent preclinical studies and a handful of human case reports have shown that FMT might be exploited to reduce motor and non-motor symptoms, as well as constipation, at least in the short term [40,465,469,470,471,472,473,474,475,476,477] (Table 4).”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [476]
In the citing paper
“On the whole, from a clinical point of view, better and longer-term outcomes were obtained using colonoscopy compared to nasointestinal delivery [476].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [476]
In the citing paper
“Within this context, 6 cases of adverse events occurred in human studies: flatulence (1), diarrhea (2), hospitalization under observation (1) and GI pain (2) [476,477].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [476]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924 · cited 1×
“The PD patients often suffer from motor symptoms including rigidity, bradykinesia, tremor, impaired balance, and also nonmotor symptoms such as sleep disturbance, anxiety, depression, cognitive deficits.([4]) These symptomsworsen over time, becoming severe enough to interfere with daily common activities, thus necessi…”
BackgroundDorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems.
(2015) · PubMed Central · Cited by 2,540
Kim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397 · cited 1×
“spread to brain along the vagus nerve.([10]) The findings of these studies provide a basis for the treatment of PD by targeting the gut.”
BackgroundThe gut microbiome in neurological disorders
Cryan, J. F., O'Riordan, K. J., Sandhu, K., Peterson, V., & Dinan, T. G. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30356-4 · Cited by 1,336 · cited 1×
“Imbalances in the gut microbiota promote altered host-microbial interactions that mediate the progression of many neurological diseases, including depression, autism, PD, etc.([6]) It has been reported that the gut microbiota in PD patients significantly differ from that of healthy individuals.”
BackgroundPrevalence of Parkinson’s disease across North America
Marras, C., Beck, J. C., Bower, J. H., Roberts, E., Ritz, B., Ross, G. W., Abbott, R. D., Savica, R., Van Den Eeden, S. K., Willis, A. W., et al. (2018) · npj Parkinson's Disease · doi:10.1038/s41531-018-0058-0 · Cited by 968 · cited 1×
“Approximately 930,000 people will be living with a PD diagnosis in the United States in 2020.([2]) In China, PD constitutes a serious public health burden, affecting approximately 1.”
BackgroundDiscovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019) · Science · doi:10.1126/science.aau6323 · Cited by 753 · cited 12×
“In fact, it is unclear which kind of microbiota can improve the symptoms of PD.”
BackgroundInfluentialSun, M.-F., Zhu, Y.-L., Zhou, Z.-L., Jia, X.-B., Xu, Y.-D., Yang, Q., Cui, C., & Shen, Y.-Q. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.02.005 · Cited by 736 · cited 12×
“In fact, it is unclear which kind of microbiota can improve the symptoms of PD.”
BackgroundInfluentialKao, D., Roach, B., Silva, M., Beck, P., Rioux, K., Kaplan, G. G., Chang, H.-J., Coward, S., Goodman, K. J., Xu, H., et al. (2017) · JAMA · doi:10.1001/jama.2017.17077 · Cited by 615 · cited 1×
“Regardless of the microbiota transplantation route, there is a satisfactory cure rate.([26]) But in IBD, the microbiota transplantation route may affect the efficacy of FMT.”
BackgroundAnxiety, depression, and the microbiome: A role for gut peptides
Lach, G., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0585-0 · Cited by 573 · cited 1×
“Gut microbiota and its metabolites may regulate neuroinflammation.([21,22]) A speculation worth noting is that FMT changes the gut microbiota and its metabolites by optimizing the structure of gut microbiota, and then improves the non-motor symptoms of PD.”
Background
Cited by
Chen, Y., Xu, J., & Chen, Y. (2021) · Nutrients · doi:10.3390/nu13062099 · Cited by 917
Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options
Hrncir, T. (2022) · Microorganisms · doi:10.3390/microorganisms10030578 · Cited by 433
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
Zhang, X., Tang, B., & Guo, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00392-8 · Cited by 187
Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
Zhu, M., Liu, X., Ye, Y., Yan, X., Cheng, Y., Zhao, L., Chen, F., & Ling, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937555 · Cited by 177
MacMahon Copas, A. N., McComish, S. F., Fletcher, J. M., & Caldwell, M. A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.666737 · Cited by 173
Metadata
- Authors
- Xue, L.-J., Yang, X.-Z., Tong, Q., Shen, P., Ma, S.-J., Wu, S.-N., Zheng, J.-L., & Wang, H.-G.
- Affiliations
- Department of Neurology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University
- Department of Gastroenterology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huaian, Jiangsu Province, China.
- Huaian First People’s Hospital (CN)
- Venue
- Medicine
- Published
- 2020-08-28
- Volume
- 99
- Issue
- 35
- Pages
- e22035
- ISSN
- 0025-7974 (ISSN-L)
- 1536-5964
- PMC
- PMC7458210
- OpenAlex
- W3081450923
- Cited by
- 186
- References
- 28
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 39 · 2023: 33 · 2022: 36 · 2021: 31 · 2020: 2
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicine (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- fecal microbiota transplantation, Parkinson's disease, gut microbiota, motor symptoms, non-motor symptoms, treatment efficacy, treatment safety, adverse events, UPDRS-III, PDQ-39
- MeSH terms
- Fecal Microbiota Transplantation, Aged, Colonoscopy, Female, Humans, Intubation, Gastrointestinal, Male, Middle Aged, Parkinson Disease, Pilot Projects, Patient Satisfaction, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fecal microbiota transplantation therapy for Parkinson's disease: A preliminary study. https://app.cochat.ai/papers/10.1097/md.0000000000022035
- The paper
- Xue, L.-J., Yang, X.-Z., Tong, Q., Shen, P., Ma, S.-J., Wu, S.-N., Zheng, J.-L., & Wang, H.-G. (2020). Fecal microbiota transplantation therapy for Parkinson's disease: A preliminary study. Medicine. https://doi.org/10.1097/md.0000000000022035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.